logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses.

    Article - En anglais

    Background 

    Previous estimates of the national economic burden of allergic rhinoconjunctivitis (AR/AC) have relied on data analyses in which AR/AC was the primary International Classification of Diseases-ninth revision-Clinical Modification (ICD-9-CM) - coded diagnosis.

    These studies ignore the costs when AR/AC was a secondary diagnosis to other disorders such as asthma and sinusitis.

    Objective 

    We sought to determine the national direct cost of illness for AR/AC.

    Methods 

    An expert panel used the Delphi technique to estimate the proportion of visits coded by other primary ICD-9-CM diagnoses in which AR/AC was a significant secondary comorbid condition.

    The costs of this proportion were deemed to be attributable'to AR/AC and were added to the costs when allergic rhinitis and allergic conjunctivitis were the primary diagnoses.

    Results 

    The cost when AR/AC was the primary diagnosis was $1.9 billion (in 1996 dollars).

    The cost when AR/AC was a secondary diagnosis was estimated at $4.0 billion, giving an estimate of $5.9 billion for the overall direct medical expenditures attributable to AR/AC.

    Outpatient services (63%, $3.7 billion), medications (25%, $1.5 billion), and inpatient services (12%, $0.7 billion) accounted for the expenditures.

    Children 12 years and younger accounted for $2.3 billion (38.0%). Conclusion : Upper airway allergy is an expensive disease process because of its readily apparent manifestations as AR/AC and its contribution to other airway disorders.

    Mots-clés Pascal : Rhinite, Allergie, Conjonctivite, Coût, Economie santé, Age, ORL pathologie, Nez pathologie, Immunopathologie, Oeil pathologie, Conjonctive pathologie

    Mots-clés Pascal anglais : Rhinitis, Allergy, Conjunctivitis, Costs, Health economy, Age, ENT disease, Nose disease, Immunopathology, Eye disease, Conjunctiva disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0187233

    Code Inist : 002B30A01C. Création : 16/11/1999.